パクリタキセル・リグルメクス、パクリタキセル・・リグルメクス

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 非プラチナ製剤ベースの癌化学療法の神経学的合併症の概要 overview of neurologic complications of non platinum cancer chemotherapy
2. 膀胱および泌尿器の転移性尿路上皮癌の治療 treatment of metastatic urothelial cancer of the bladder and urinary tract
3. 進行（ステージIIIまたはIV）上皮性卵巣癌、卵管癌、および腹膜癌に対する初回化学療法 first line chemotherapy for advanced stage iii or iv epithelial ovarian fallopian tubal and peritoneal cancer
4. 薬剤溶出性冠動脈ステントの比較 comparison of drug eluting intracoronary stents
5. 限局進行性および切除可能境界膵外分泌癌に対する初回化学療法および放射線治療 initial chemotherapy and radiation for nonmetastatic locally advanced unresectable borderline resectable and potentially resectable exocrine pancreatic cancer

English Journal

PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study: BrUOG 244.

Elinzano H1, Glantz M, Mrugala M, Kesari S, Piccioni DE, Kim L, Pan E, Yunus S, Coyle T, Timothy K, Evans D, Mantripragada K, Boxerman J, DiPetrillo T, Donahue JE, Hebda N, Mitchell KM, Rosati KL, Safran H.
American journal of clinical oncology.Am J Clin Oncol.2015 Dec 9. [Epub ahead of print]
PURPOSE: Efficacy signals but substantial myelosuppression were demonstrated in a single arm phase II study of paclitaxel poliglumex (PPX) in combination with temozolomide (TMZ) and radiation therapy (RT) for first-line treatment of glioblastoma. The objective of this randomized phase II trial was t
PMID 26658237

Growth Attenuation of Cutaneous Angiosarcoma With Propranolol-Mediated β-Blockade.

Chow W1, Amaya CN2, Rains S2, Chow M1, Dickerson EB3, Bryan BA2.
JAMA dermatology.JAMA Dermatol.2015 Nov;151(11):1226-9. doi: 10.1001/jamadermatol.2015.2554.
IMPORTANCE: Patients with stage T2 multilesion angiosarcomas of the scalp and face that are larger than 10 cm demonstrate a 2-year survival rate of 0%. To our knowledge, major therapeutic advances against this disease have not been reported for decades. Preclinical data indicate that blocking β-adr
PMID 26375166

Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma.

Boxerman JL1, Ellingson BM, Jeyapalan S, Elinzano H, Harris RJ, Rogg JM, Pope WB, Safran H.
American journal of clinical oncology.Am J Clin Oncol.2014 Nov 26. [Epub ahead of print]
OBJECTIVE:: For patients with high-grade glioma on clinical trials it is important to accurately assess time of disease progression. However, differentiation between pseudoprogression (PsP) and progressive disease (PD) is unreliable with standard magnetic resonance imaging (MRI) techniques. Dynamic
PMID 25436828